The EPS projection of EnteroMedics Inc. (NASDAQ:ETRM) for quarter ended 2016-09-30 is $-0.67. Last week, the EPS forecast was $-0.67 against target of $-0.67, a month earlier. Two months ago, this estimate was $-0.67 versus forecast of $-0.67 three months earlier, implying a deviation of 0%.
EnteroMedics Inc. (NASDAQ:ETRM) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 0, and 0, correspondingly.
EPS estimate downgrade for EnteroMedics Inc. (NASDAQ:ETRM) in the preceding 30, 120, 60 and 90 days were 1, 1, 1, and 1, correspondingly.
EnteroMedics Inc. (NASDAQ:ETRM) EPS target for the quarter closed 1 was $-0.67, based on 2 recommendations. As reported on 2016-05-05 the EPS was $-0.82. The change was $-0.02, implying a percentage deviation of -2.5%. The projections showed a standard deviation of 0.
Quarterly Sales Estimates
EnteroMedics Inc. (NASDAQ:ETRM) yearly sales prediction for the fiscal 2016 stands at $0.295 and the median estimate is at $0.295. Almost 2 analysts issued sales target.
Highest sales target is $0.39 while the lowest target is $0.2 showing standard deviation of 0.134%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of 47.5%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. EnteroMedics Inc. (NASDAQ:ETRM) announced that the deviation in forecast was -47.787%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...